A Study to Learn About How Different Forms of Study Medicine PF-07248144 Are Taken Up Into the Blood in Healthy Adults

Not Applicable

Completed

• Conditions: Healthy Adults
• Interventions: Drug: PF-07248144

• Registration Number: NCT07117799
• Lead Sponsor: Pfizer

Brief Summary

Study has two arms. Arm 1 has two cohorts in which each cohort, under the fasted state, will either be given a single oral dose of Form 1 in Period 1 followed by a single oral dose of Form 5 in Period 2 or a single oral dose of Form 5 in Period 1 followed by a single oral dose of Form 1 in Period 2. A single oral dose of Form 1 will be administered in Arm 2 Period 1 under the fasted state. The results from Arm 1 will inform whether a different dose of Form 5 will be administered under the fasted state or if Form 5 will be administered under the fed state in Arm 2 Period 2.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-02-04
• Primary Completion: 2025-07-11
• Study Completion: 2025-07-11
• Status Verified: 2025-08
• Study First Submitted: 2025-08-05
• Study First Submitted QC: 2025-08-05
• Last Update Submitted: 2025-08-05
• Study First Posted: 2025-08-12
• Last Update Posted: 2025-08-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
PF-07248144 Form 1 (uncoated) Arm	PF-07248144	Period 1: Participants received Form 1 in a single dose of tablet fasted Period 2: Participants received Form 5 in a single dose of tablet fasted
PF-07248144 Form 5 (film-coated) Adaptive Arm	PF-07248144	Period 1: Fasted participants received a single dose of tablet of Form 1 orally Period 2: Participants received a single dose of tablet orally of Form 5 in a fed state
PF-07248144 Form 5 (film-coated) Arm	PF-07248144	Period 1: Participants received Form 5 in a single dose of tablet fasted Period 2: Participants received Form 1 in a single dose of tablet fasted

Primary Outcome Measures

Name	Time	Method
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-07248144 Form 1 uncoated tablet	0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, and 168 hours post-dose
AUCinf for PF-07248144 Form 5 film-coated tablet	0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, and 168 hours post-dose
Maximum Observed Plasma Concentration (Cmax) for PF-07248144 Form 1 uncoated tablet	0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, and 168 hours post-dose
Cmax for PF-07248144 Form 5 film-coated tablet	0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, and 168 hours post-dose

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria	From Baseline up to Day 35
Number of Participants With Clinically Significant Physical Examination Abnormalities	From Baseline up to Day 35
Number of Participants With Treatment Emergent Treatment Related AEs and SAEs	From Baseline up to Day 35
Number of Participants With Laboratory Test Abnormalities	From Baseline up to Day 35

Trial Locations

Locations (1)

Pfizer Clinical Research Unit - New Haven; 🇺🇸 New Haven, Connecticut, United States